Tri Locum Partners LP Madrigal Pharmaceuticals, Inc. Transaction History

Tri Locum Partners LP

$278 Million
Q2 2025

A detailed history of Tri Locum Partners LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Tri Locum Partners LP holds 97,765 shares of MDGL stock, worth $44 Million. This represents 10.65% of its overall portfolio holdings.

Number of Shares

97,765

Previous 37,869 158.17%

Holding current value

$44 Million

Previous $12.5 Million 135.88%

% of portfolio

10.65%

Previous 7.49%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$267.56 - $340.8 $16 Million - $20.4 Million	59,896 Added 158.17%	97,765 $29.6 Million
Q1 2025 May 14, 2025	SELL	$272.79 - $355.88 $2.62 Million - $3.42 Million	-9,603 Reduced 20.23%	37,869 $12.5 Million
Q4 2024 Feb 14, 2025	BUY	$202.45 - $354.85 $847,253 - $1.49 Million	4,185 Added 9.67%	47,472 $14.6 Million
Q3 2024 Nov 14, 2024	SELL	$212.22 - $292.96 $4.68 Million - $6.46 Million	-22,065 Reduced 33.76%	43,287 $9.19 Million
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $2.32 Million - $3.5 Million	11,997 Added 22.49%	65,352 $18.3 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $4.77 Million - $7.88 Million	27,831 Added 109.04%	53,355 $14.2 Million
Q4 2023 Feb 14, 2024	SELL	$120.4 - $237.13 $991,734 - $1.95 Million	-8,237 Reduced 24.4%	25,524 $5.91 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $1.13 Million - $1.75 Million	7,751 Added 29.8%	33,761 $4.93 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $2.48 Million - $3.8 Million	12,165 Added 87.87%	26,010 $6.01 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $2.9 Million - $3.85 Million	-12,541 Reduced 47.53%	13,845 $3.35 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $1.54 Million - $7.82 Million	26,386 New	26,386 $7.66 Million

Others Institutions Holding MDGL

# of Institutions

356

Shares Held

23.2M

Call Options Held

738K

Put Options Held

473K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $7.69B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.

Account

Tri Locum Partners LP Madrigal Pharmaceuticals, Inc. Transaction History